For the latest COVID-19 (Coronavirus) information: CCTG public updates | CCTG member information

Partnerships: Industry & Academic

Partnerships: Industry & Academic
Engaging Industry and Academic Partners

CCTG is know for cancer clinical trial research and is the world's largest cooperative collaborative oncology group. Our success is realized through our network of investigators who develop scientifically important and meaningful trials, conducted both rapidly and to rigorous standards. With over 40 years of experience there is no network that rivals the depth and breadth of operations with a global reputation for rapid execution of quality clinical trials.

Partnerships

National and international collaboration

Industry partnerships

While CCTG trials are independently conducted, analyzed and reported. Pharmaceutical or academic drug manufacturers provide CCTG access to their investigational new drugs because they recognize the high quality research being conducted through the group.

CCTG receives matching infrastructure award from The Ontario Research Fund

(left to right) Shakeel Virk, Director Operations & Pathology Coordinator of the CCTG Tumour Tissue Data Repository, Dr David LeBrun, Academic Director, Queen's Laboratory for Molecular Pathology, Ms. Sophie Kiwala, MPP for Kingston and the Islands, Dr Lois Shepherd Director of the CCTG Tumour Tissue Data Repository, Dr. Madhuri Koti, Queen's University (back) Dr. John Fisher, Vice-Principal (Research), Queen’s University.

More >>
 
Cancer Research Institute and Canadian Cancer Trials Group Announce Strategic Collaboration

Cancer Research Institute and Canadian Cancer Trials Group Announce Strategic Collaboration

The Cancer Research Institute (CRI) and the Canadian Cancer Trials Group (CCTG) have announced a multi-year collaboration to develop and conduct clinical trials in immunotherapy.

More >>
 
Dr. Janet Dancey, CCTG Director and JELF award recipient

Precision Oncology takes a step forward at CCTG

The Canadian Foundation for Innovation (CFI) John R. Evans Leaders Fund (JELF) has announced a funding award of $197,065 to allow the Canadian Cancer Trials Group (CCTG) to acquire a state-of-the-art digital histology slide scanner.

More >>
 
The trial is changing how brain cancer is treated in older patients around the world

Brain cancer treatment gets much-needed boost

Dr Christopher O’Callaghan knows the impact that glioblastoma, an aggressive form of brain cancer, can have on families. His father was diagnosed at a time when the only available treatment was radiation. But now, thanks to Dr O’Callaghan’s research with the Canadian Cancer Trials Group (CCTG), there are better treatment options for patients with glioblastoma.

More >>